FibriCheck’s 2025 wrap-up

With 2025 coming to an end, we’re proud to look back on a year defined by major progress. With significant product improvements, powerful clinical validation, and new partnerships, we continued advancing our mission to make reliable heart health measurements accessible for all.

2025 in numbers: our user metrics unpacked

This year we enlarged our impact, with over 250.000 blood pressure logs, 45.000 weight logs and 40.000.000 heart rhythm measurements processed. We monitored over 30.000.000 patient days in 2025 and registered over 820.000.000 heart beats in various countries all over the world, meeting the most stringent compliance requirements for medical devices such as FDA and CE regulations.

Strengthening our U.S. footprint

FibriCheck’s recognition by the FDA, being included on both the list of AI-enabled medical devices and devices incorporating sensor-based digital health technology, underscores the safety, effectiveness, and innovative nature of our technology. Our presence in the U.S. continues to grow as we are now fully incorporated and have achieved several exciting milestones over the course of 2025.  One of those milestones was launching a pilot program with the Midwest Cardiovascular Institute, where our non-invasive PPG technology was used to remotely monitor patients after AF ablation procedures, improving the continuity of care. 

We have also participated in several prestigious accelerator programs which allowed us to grow our U.S. network, test and validate our value in real-world settings, and to take part in several clinical studies. We were accepted into the AgeTech Collaborative from AARP, graduated from the Texas Medical Center Innovation Factory, and have recently also been accepted as one of just seven startups for the 2025 HeartX Accelerator. 

Accelerating our impact across Europe

Our European growth continues to gain momentum, as we doubled our footprint last year through new integrations, partnerships, and large-scale implementations. 

Our partnerships with insurers prove to be a success, as our collaboration with Benenden Health already enabled over 40.000 rhythm checks in 2025, thereby providing reassurance to thousands, avoiding unnecessary care escalation, and enabling early AF detection when it matters most.

Belgian insurers Helan and CM also saw an exponential rise in the number of heart rhythm measurements of their users, with a total of over 1 million heart rhythm measurements performed to date. 

Meanwhile, our integration with the Ultrahuman Ring has enabled the analysis of millions of nocturnal PPG measurements over the past year, as we are processing about 2500 measurements per hour, 24/7. The results of these measurements deliver rich insights into AF, non-AF irregular rhythms, and complex cardiac patterns during sleep. This proven, medical-grade implementation is now supporting a rapidly growing user base with unprecedented continuity and accuracy.

Several new hospitals including Noorderhart Hospital, Spaarne Hospital and Leeds Teaching Hospitals NHS Trust started using FibriCheck in various care pathways for heart rhythm irregularities and heart failure. Our seamless integration into existing workspaces enables the swift adoption of our technology. We are integrated with EPIC and KWS systems, allowing clinicians to create prescriptions and to monitor their patients’ heart rhythm directly within their own workflow.

Finally, we have launched a major community pharmacy AF screening initiative across South London and are now also featured on the Pharmacy2U App Hub, launched in partnership with ORCHA to bring safe, clinically validated digital health tools to millions of consumers. 

A year of exciting quality upgrades

Our already best-in-class accuracy of 99% was strengthened even further through an upgraded algorithm, reducing the rate of uninterpretable readings by another 10%. This upgrade resulted in time savings and reduced frustration for users, leading to greater trust and motivation. At the same time, this upgrade also boosted the diagnostic yield of FibriCheck to detect 2.4% more cases of atrial fibrillation. 

FibriCheck allows you to build your own custom-tailored care and communication pathways

This year, we focused on giving our partners more control over how FibriCheck supports their care pathways. Hospitals and payers can now:

• Configure custom monitoring rules and alerts for triggering actions, faster triage and follow-up
• Design workflow steps with patient-reported outcomes, confirmations and repeat-measurement requests
• Add tailored communication and education pathways, from post-ablation follow-up to insurer-focused programs

These building blocks make it easy to adapt FibriCheck to any clinical setting and stakeholder, without extra IT work.

Validated in research, trusted in real-world care

This year, we strengthened our role as a valuable partner in clinical research, demonstrating how our hardware-free technology supports faster, smarter, and more cost-effective studies by simplifying data collection and reducing the need for intensive site infrastructure. A key highlight was our involvement in the CRAAFT-HF trial, where the first 20 centers are up and running. The CRAAFT-HF trial is a study building on the CASTLE-AF and CABANA trials to explore the benefits of ablation in a broader heart failure population, where FibriCheck is helping generate crucial real-world evidence to evaluate outcomes. We also saw promising results in the TeleConvert-AF study, where 270 patients with presumed persistent AF used FibriCheck before elective cardioversion. Rhythm monitoring detected spontaneous conversion to sinus rhythm or paroxysmal AF in 13.7% of cases, preventing unnecessary cardioversion procedures.

Various studies exploring our accuracy also delivered powerful validation of our technology. The prospective cohort study by Kamsani et al. showed no significant difference between mean heart rate measured using FibriCheck versus Holter, with outstanding AF detection performance (Sensitivity 100%, Specificity 99.8%, Accuracy 99.8%). A large multi-center and multi-national cohort was published in Nature Digital Health and also confirmed FibriCheck’s exceptional accuracy across smartphone models (Accuracy 98.5%, Sensitivity 96.3%, Specificity 99.3%). A validation study by Wouters et al. demonstrated that FibriCheck outperformed 6-lead handheld and smartwatch ECG devices in specificity and overall accuracy when compared to the 12-lead ECG gold standard. Another study presented at the World Stroke Congress demonstrated FibriCheck’s promising AF detection rate of 12% for patients who have suffered a TIA, far surpassing the 1–2% detection rate achieved through standard ECG. FibriCheck’s findings were confirmed for all cases by ECG examinations. Together, these study results reinforce FibriCheck as a clinically robust solution for real-world AF detection and monitoring. 

This year, the FibriCheck Academy expanded its educational offering with the introduction of a dedicated section focused on special PPG cases and measurement examples. This new resource supports clinicians by providing real-case scenarios that can be used for continued learning and skills development. 

We’re looking forward to 2026!

With a new year ahead, we’re grateful for the progress made in 2025 and for the trust our partners and users place in us. In 2026, we look forward to strengthening our existing collaborations, welcoming new partnerships, advancing clinical research, and continuing to support our users throughout their heart health journey.